Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

Evommune, Inc. (EVMN) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

Evommune, Inc. (EVMN), most recent 12 months reported: revenue $10M, net loss $94.67M, free cash flow -$74.65M. Latest balance sheet on file: liquid cash $200.79M. From SEC filings. Others in Pharmaceutical Preparations: PALATIN TECHNOLOGIES, INC. · CV Sciences, Inc. · CRESCENT BIOPHARMA, INC. · BIOAGE LABS, INC. · Zenas BioPharma, Inc. · Opus Genetics, Inc. · PRECIGEN, INC. · INTERNATIONAL STEM CELL CORPORATION

Stock screener

Watchlist